Xtampza ER (Oxycodone Myristate) Patent Expiration, LOE Window & CMS Spending

Xtampza ER (Oxycodone Myristate) by Collegium: FDA Orange Book LOE 2036-09-02, 14 AB generics, $260.6M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCollegium
FDA Application & PathwayN208090 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-09-02
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$260.6M
2024 Medicare Part D Spend$232.8M
2024 Medicaid Spend$27.9M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 26.8% 2-yr change)